Wave Life Sciences Advances Obesity and RNA Editing Pipeline with Key 2026 Milestones
Event summary
- Wave Life Sciences reported $602.1 million in cash as of December 31, 2025, with a runway into Q3 2028.
- WVE-007 (INHBE GalNAc-siRNA) showed fat loss similar to GLP-1 in Phase 1 trials, with data updates expected in Q1 2026.
- Phase 2a multidose trials for WVE-007 in obesity patients with higher BMI and comorbidities planned for H1 2026.
- WVE-006 (GalNAc-RNA editing) for AATD achieved dynamic AAT production over 20 micromolar, with regulatory feedback expected mid-2026.
- CTA submission for WVE-008 (PNPLA3 I148M liver disease) on track for 2026.
The big picture
Wave Life Sciences is positioning itself as a leader in RNA medicines, with a focus on obesity and genetic disorders. The company's strategic shift toward RNA editing and siRNA technologies aims to address unmet medical needs, while its financial stability provides a strong foundation for clinical advancements. The broader biotech industry is watching closely as Wave's pipeline could redefine treatment paradigms for conditions like obesity and AATD.
What we're watching
- Clinical Efficacy
- Whether WVE-007 can sustain fat loss comparable to GLP-1 at higher doses and longer follow-up.
- Regulatory Pathway
- The pace at which WVE-006 advances through accelerated approval for AATD.
- Pipeline Progression
- How Wave Life Sciences balances multiple clinical trials while maintaining financial runway.
Related topics